×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RNAZ – transcode therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RNAZ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/15
08:03 am
rnaz
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Medium
Report
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
11/12
07:00 am
rnaz
TransCode Therapeutics Open Letter to Shareholders
Medium
Report
TransCode Therapeutics Open Letter to Shareholders
11/5
07:00 am
rnaz
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
High
Report
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
10/24
08:08 am
rnaz
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Medium
Report
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
10/23
07:00 am
rnaz
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
High
Report
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
10/10
07:00 am
rnaz
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
High
Report
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
9/17
07:00 am
rnaz
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
High
Report
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
9/10
07:00 am
rnaz
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
Low
Report
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:32 pm
rnaz
Form 10-Q Transcode Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Transcode Therapeutics, For: Sep 30
11/13
04:35 pm
rnaz
Form DEFA14A Transcode Therapeutics,
Medium
Report
Form DEFA14A Transcode Therapeutics,
11/6
04:05 pm
rnaz
Form SC 13G/A Transcode Therapeutics, Filed by: 3i, LP
Low
Report
Form SC 13G/A Transcode Therapeutics, Filed by: 3i, LP
11/6
04:02 pm
rnaz
Form DEFA14A Transcode Therapeutics,
Low
Report
Form DEFA14A Transcode Therapeutics,
11/6
04:01 pm
rnaz
Form 8-K Transcode Therapeutics, For: Nov 04
Low
Report
Form 8-K Transcode Therapeutics, For: Nov 04
10/28
04:03 pm
rnaz
Form DEF 14A Transcode Therapeutics, For: Nov 22
Medium
Report
Form DEF 14A Transcode Therapeutics, For: Nov 22
10/15
05:24 pm
rnaz
Form PRE 14A Transcode Therapeutics, For: Oct 15
Medium
Report
Form PRE 14A Transcode Therapeutics, For: Oct 15
9/27
04:03 pm
rnaz
Form 8-K Transcode Therapeutics, For: Sep 23
High
Report
Form 8-K Transcode Therapeutics, For: Sep 23
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: